These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 30742942)

  • 21. FRET biosensor-based kinase inhibitor screen for ERK and AKT activity reveals differential kinase dependencies for proliferation in TNBC cells.
    He J; Wink S; de Bont H; Le Dévédec S; Zhang Y; van de Water B
    Biochem Pharmacol; 2019 Nov; 169():113640. PubMed ID: 31536726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
    Ripple MO; Kalmadi S; Eastman A
    Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inverse agonist of estrogen-related receptor α suppresses the growth of triple negative breast cancer cells through ROS generation and interaction with multiple cell signaling pathways.
    Wu YM; Chen ZJ; Jiang GM; Zhang KS; Liu Q; Liang SW; Zhou Y; Huang HB; Du J; Wang HS
    Oncotarget; 2016 Mar; 7(11):12568-81. PubMed ID: 26871469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
    Wu C; Qiu S; Liu P; Ge Y; Gao X
    J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways.
    Bai X; Ali A; Lv Z; Wang N; Zhao X; Hao H; Zhang Y; Rahman FU
    Eur J Med Chem; 2021 Nov; 224():113689. PubMed ID: 34293698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer.
    van der Noord VE; McLaughlin RP; Smid M; Foekens JA; Martens JWM; Zhang Y; van de Water B
    Sci Rep; 2019 Sep; 9(1):13308. PubMed ID: 31527768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Norcantharidin induces apoptosis in HeLa cells through caspase, MAPK, and mitochondrial pathways.
    An WW; Gong XF; Wang MW; Tashiro S; Onodera S; Ikejima T
    Acta Pharmacol Sin; 2004 Nov; 25(11):1502-8. PubMed ID: 15525474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.
    Li Y; Xiao Y; Lin HP; Reichel D; Bae Y; Lee EY; Jiang Y; Huang X; Yang C; Wang Z
    Biomaterials; 2019 Jan; 188():160-172. PubMed ID: 30352320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells.
    Chen YJ; Kuo CD; Tsai YM; Yu CC; Wang GS; Liao HF
    Anticancer Drugs; 2008 Jan; 19(1):55-64. PubMed ID: 18043130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells.
    Chen YN; Chen JC; Yin SC; Wang GS; Tsauer W; Hsu SF; Hsu SL
    Int J Cancer; 2002 Jul; 100(2):158-65. PubMed ID: 12115564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NCTD elicits proapoptotic and antiglycolytic effects on colorectal cancer cells via modulation of Fam46c expression and inhibition of ERK1/2 signaling.
    Zhang S; Yang Y; Hua Y; Hu C; Zhong Y
    Mol Med Rep; 2020 Aug; 22(2):774-782. PubMed ID: 32468032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
    Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
    Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
    Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
    J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Norcantharidin induces cell cycle arrest and inhibits progression of human leukemic Jurkat T cells through mitogen-activated protein kinase-mediated regulation of interleukin-2 production.
    Liao HF; Chen YJ; Chou CH; Wang FW; Kuo CD
    Toxicol In Vitro; 2011 Feb; 25(1):206-12. PubMed ID: 21075198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Norcantharidin Enhances High Concentrations of Fetal Bovine Serum-Induced Apoptosis in Human Mesangial Cells by Regulating the Mitogen-Activated Protein Kinase Signaling Pathway.
    Ye K; Wei QY; Long TX; He HG; Huang YF; Xiong LJ; Lan J; Huang YY; Gong ZF; Peng XM; Wu QX
    Kidney Blood Press Res; 2019; 44(6):1339-1351. PubMed ID: 31661692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer.
    Colombo M; Rizzuto MA; Pacini C; Pandolfi L; Bonizzi A; Truffi M; Monieri M; Catrambone F; Giustra M; Garbujo S; Fiandra L; Corsi F; Prosperi D; Mazzucchelli S
    Bioconjug Chem; 2018 Nov; 29(11):3817-3832. PubMed ID: 30350574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cooperation between p21 and Akt is required for p53-dependent cellular senescence.
    Kim YY; Jee HJ; Um JH; Kim YM; Bae SS; Yun J
    Aging Cell; 2017 Oct; 16(5):1094-1103. PubMed ID: 28691365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
    Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
    Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
    Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway.
    Zhang JT; Sun W; Zhang WZ; Ge CY; Liu ZY; Zhao ZM; Lu XS; Fan YZ
    BMC Cancer; 2014 Mar; 14():193. PubMed ID: 24628713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.